Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GDTC 
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: GDTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.1% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.64M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.36 | 52 Weeks Range 1.20 - 4.05 | Updated Date 09/15/2025 |
52 Weeks Range 1.20 - 4.05 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -530.32% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -24.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23119163 | Price to Sales(TTM) 52.91 |
Enterprise Value 23119163 | Price to Sales(TTM) 52.91 | ||
Enterprise Value to Revenue 426.37 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11733700 | Shares Floating 3593787 |
Shares Outstanding 11733700 | Shares Floating 3593787 | ||
Percent Insiders 68.86 | Percent Institutions 0.43 |
Upturn AI SWOT
CytoMed Therapeutics Limited Ordinary Shares
Company Overview
History and Background
CytoMed Therapeutics Limited is a Singapore-based biopharmaceutical company focused on developing cancer immunotherapies. It leverages its proprietary technologies to engineer and develop novel T cell-based therapies for hard-to-treat cancers.
Core Business Areas
- Cell Therapy Development: Research, development, and clinical trials of cell-based immunotherapies, primarily focusing on engineered T cells.
- CAR-CIK Technology: Development and optimization of Chimeric Antigen Receptor Cytokine-Induced Killer (CAR-CIK) technology for cancer treatment.
- Preclinical Research: Conducting preclinical studies to evaluate the safety and efficacy of novel therapeutic candidates.
Leadership and Structure
The company is led by a management team with expertise in oncology, immunology, and drug development. The organizational structure is typical for a biotech company, with research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- CM-CDK1-CAR-CIK: A CAR-CIK therapy targeting CDK1, a protein overexpressed in several solid tumors. Currently in preclinical development and early stage trials. Competitors are other CAR-T and CAR-NK cell therapy developers like Novartis, Gilead, and Bristol Myers Squibb.
- CM-CS1-CAR-CIK: CAR-CIK therapy targeting CS1, a protein expressed in multiple myeloma. Currently in early stage clinical trials. Competitors are other cell therapy developers in multiple myeloma, including Johnson & Johnson and bluebird bio.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by increasing success in treating hematological cancers and expanding applications in solid tumors. High unmet need and technological advancements are fueling growth.
Positioning
CytoMed is a relatively small player in the cell therapy market, focused on developing novel CAR-CIK therapies for specific cancer targets. Its competitive advantage lies in its proprietary CAR-CIK technology platform and focus on Asian markets.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of USD. CytoMed is positioned to capture a portion of this market with its targeted therapies. TAM is expected to reach over $80 Billion by 2030. CytoMed is a small player with potential for growth, currently capturing a very small percentage of the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary CAR-CIK technology platform
- Focus on Asian markets with high cancer prevalence
- Experienced management team
- Targeting of difficult-to-treat cancers
Weaknesses
- Limited financial resources compared to larger competitors
- Early stage development pipeline
- Dependence on preclinical and clinical trial success
- Relatively unknown company in the US
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in cell therapy manufacturing
- Regulatory approvals in key markets
Threats
- Competition from established cell therapy companies
- Clinical trial failures
- Regulatory hurdles
- High cost of cell therapy development
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- JNJ
- BLUE
Competitive Landscape
CytoMed faces intense competition from larger, well-established pharmaceutical companies with extensive resources and established cell therapy products. CytoMed needs to successfully navigate its clinical trials to reach market maturity.
Growth Trajectory and Initiatives
Historical Growth: Growth primarily driven by progress in preclinical and clinical development. Historic revenue growth is minimal.
Future Projections: Future growth dependent on clinical trial success, regulatory approvals, and commercialization of its cell therapies. Analyst estimates are not readily available.
Recent Initiatives: Focus on advancing lead CAR-CIK candidates through clinical trials.
Summary
CytoMed Therapeutics is a small Singapore-based biotech company focused on developing CAR-CIK therapies. The company's strength lies in its proprietary technology, but it faces significant challenges including limited financial resources and intense competition. Successful clinical trials and partnerships will be crucial for its future growth. CytoMed has a small fraction of the total addressable market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, Industry reports, SEC filings of competitors
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://w2.cytomed.sg |
Full time employees 43 | Website https://w2.cytomed.sg | ||
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.